Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review-Reference-Cited by-同舟云学术

Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review

Published:2019-10-24 Issue:2 Volume:20 Page:169-185
ISSN:1473-7159
Container-title:Expert Review of Molecular Diagnostics
language:en
Short-container-title:Expert Review of Molecular Diagnostics

Author:

Rebuzzi Sara Elena¹²,Perrone Fabiana¹,Bersanelli Melissa¹³,Bregni Giacomo²,Milella Michele⁴,Buti Sebastiano¹^ORCID

Affiliation:

1. Medical Oncology Unit, University Hospital of Parma, Parma, Italy

2. Department of Medical Oncology, IRCCS San Martino IST, Genova, Italy

3. Department of Medicine and Surgery, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy

4. Section of Medical Oncology, Department of Medicine, University of Verona and University Hospital Trust, Verona, Italy

Publisher

Informa UK Limited

Subject

Genetics,Molecular Biology,Molecular Medicine,Pathology and Forensic Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737159.2019.1680286

Reference64 articles.

1. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours

2. Cancer statistics, 2019

3. Chemotherapy in metastatic renal cell cancer

4. Chemotherapeutic strategies for renal cell carcinoma

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab;Immunotherapy;2024-08-19

2. Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study;Frontiers in Immunology;2024-07-05

3. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study;Cancer Immunology, Immunotherapy;2024-07-02

4. Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study);Future Oncology;2024-06-12

5. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study;2024-02-28